|
Phyton Biotech is the pioneer of commercial plant cell fermentation for production of small molecules and is developing this technology to encompass recombinant proteins.
The Plant Alternative: Proteins
Higher plant cells are eukaryotic and therefore able to express genes from all sources and correctly synthesize proteins of nearly all types. It does not matter if the genes come from a bacterial, fungal, plant, animal or human source. The protein from transgenic plant cells will be similar to the native source, because it will have the same amino acid sequence and the same folding pattern. If the protein needs to be post-translationally modified, a plant cell expression system can be engineered to install glycosylation and other post-translational modifications that are similar to the modifications that mammalian cells provide.
Secondary Plant Metabolites - Small Molecules
The plant kingdom's more than 250,000 species produce an amazing number of chemical entities, yet most of these entities have never been investigated for their medicinal properties. Plants remain underutilized as a source for novel drugs. The primary reasons are uncertain re-supply of plant material following discovery of active substances, especially for endangered or slow growing species, and the potential complexity of synthetic routes to commercial production. Phyton Biotech's PCF technology is an integrated platform designed to solve these critical issues.
Outsource with Confidence
To address the needs of customers, Phyton Biotech has developed a streamlined, three-phase approach to commercialization, consisting of Feasibility, Process Development and Commercial Production.
Visit www.phytonbiotech.com
|
